PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER

Share this post

"These drugs have achieved the dubious distinction of being the most expensive preventive therapies by far in the history of cardiovascular medicine," says an editorial.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply